{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"13.4","value":"4.8"},{"groupId":"OG001","lowerLimit":"2.8","upperLimit":"8.3","value":"5.57"}]}]}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"382"},{"groupId":"OG001","value":"189"}],"units":"Participants"}],"description":"Duration of response will be defined as the duration from the first documentation of complete response (CR), partial response (PR) to the first documented disease progression.","dispersionType":"Full Range","groups":[{"description":"Tremelimumab 10mg/kg","id":"OG000","title":"TREMELIMUMAB"},{"description":"Placebo.","id":"OG001","title":"PLACEBO"}],"paramType":"MEDIAN","populationDescription":"ITT","reportingStatus":"POSTED","timeFrame":"Duration of response from the first documentation of objcetive response (confirmed CR or PR) to the first documented disease progression, assessed up to 14 weeks after the initial response.","title":"Duration of Response by Treatment Arm","type":"SECONDARY","typeUnitsAnalyzed":"Participants","unitOfMeasure":"Months"}